The cardiovascular outcome trials LEADER and SUSTAIN-6 for liraglutide and semaglutide, respectively, have shown a significant cardiovascular disease (CVD) risk reduction on top of standard of care in people with type 2 diabetes (T2D), at increased risk of CVD in addition to control of glycaemia. 1,2 The improved cardiovascular risk profile has been suggested to be attributed-at least partly-to the anti-inflammatory properties of these long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) independently of weight loss. 3-5 However, the physiological and cellular mechanism behind the CVD benefit has not yet been fully uncovered. Using the ApoE−/− and the Ldlr−/− mouse models of atherosclerosis, liraglutide has been demonstrated to result